Precision NanoSystems and CanSino Biologics announce agreement to
co-develop a COVID-19 RNA vaccine

20 May 2020

On May 20, 2020, CanSino Biologics Inc. ("CanSinoBIO") and Precision NanoSystems, Inc. ("PNI") announced a co-development agreement of an mRNA lipid nanoparticle (mRNA-LNP) vaccine against COVID-19.



The parties will leverage PNI's proprietary RNA vaccine platform, comprising of lipid nanoparticle delivery system and the NanoAssemblr® manufacturing technology, to rapidly advance a COVID-19 mRNA-LNP vaccine candidate towards human clinical testing and pursuant to regulatory approvals, commercialization in different regions.

PNI will be responsible for development of the mRNA-LNP vaccine formulation and CanSinoBIO will be responsible for antigen design, pre-clinical testing, human clinical trials, regulatory approval and commercialization. CanSinoBIO has rights to commercialize the vaccine product in Asia (except Japan) with PNI retaining rights for rest of the world. The agreement includes undisclosed payments and royalties.

PNI, based in Vancouver, British Columbia, is a global leader in technologies and solutions for the development and manufacture of nanomedicines. CanSinoBIO (HK: 6185) headquartered in Tianjin, China, commits to research, production and commercialization of innovative vaccines for China and global public health security.

Paul Armitage of Gowling WLG in Vancouver advised PNI on the negotiation of this agreement, with Le Rong and Nelson Tian of Gowling WLG's Guangzhou office advising on Chinese law aspects.


NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.

Related   Life Sciences